-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
CompilationFan Dongdong
A few days ago, Day One Biopharmaceuticals announced that it has signed a global license agreement with Merck to jointly develop and commercialize Pimasertib and MSC2015103B.
Pimasertib and MSC2015103B are oral, highly selective small molecule allosteric inhibitors of MEK 1/2 (key enzyme in the MAPK signaling pathway).
Day One Pharmaceuticals, located in South San Francisco, is a pharmaceutical startup.
According to the cooperation agreement between the two companies, Day One will pay Merck an upfront payment, plus other regulatory, approval, and sales-based milestone payments.
Prior to this, Pimasertib has conducted more than 10 phase 1/2 clinical trials in approximately 900 patients with various tumor types.
DAY101 is a potential, first-class, brain-permeable, highly selective type II pan-RAF kinase inhibitor under Day One.
It is worth mentioning that a large part of pediatric tumors are caused by BRAF wild-type fusion protein, not by BRAF mutations.
Reference source: Day One Expands Clinical-Stage Oncology Pipeline; Announces Global License Agreement with Merck KGaA, Darmstadt, Germany to Develop and Commercialize MEK Inhibitor Pimasertib
